Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children

• Published in: Vaccine Vol. 31; no. 48; pp. 5706 - 5712
• Main Authors: Englund, Janet A, Karron, Ruth A, Cunningham, Coleen K, LaRussa, Philip, Melvin, Ann, Yogev, Ram, Handelsman, Ed, Siberry, George K, Thumar, Bhavanji, Schappell, Elizabeth, Bull, Catherine V, Chu, Helen Y, Schaap-Nutt, Anne, Buchholz, Ursula, Collins, Peter L, Schmidt, Alexander C
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 19.11.2013; Elsevier; Elsevier Limited; Elsevier Ltd. Published by Elsevier Ltd
• Subjects: administered dose; Age; Allergy and Immunology; Antibodies, Viral - blood; Applied microbiology; Biological and medical sciences; blood serum; Child, Preschool; children; Children & youth; Clinical trials; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Ear diseases; Female; fever; Fundamental and applied biological sciences. Psychology; Hospitalization; Hospitals; Human parainfluenza virus 3; Humans; Illnesses; Immunization; Infant; Infants; Infections; Live-attenuated vaccine; Male; Microbiology; Miscellaneous; Nasal Cavity - virology; nose; Parainfluenza; Parainfluenza Vaccines - administration & dosage; Parainfluenza Vaccines - adverse effects; Parainfluenza Vaccines - genetics; Parainfluenza Vaccines - immunology; Parainfluenza virus; Parainfluenza Virus 3, Human - genetics; Parainfluenza Virus 3, Human - immunology; pathogenicity; Pediatric vaccine; Pediatrics; Placebos - administration & dosage; Recombinant virus vaccine; Respiratory diseases; Respiratory tract; Respirovirus Infections - prevention & control; Respirovirus Infections - virology; tissue culture; Vaccination - adverse effects; Vaccination - methods; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - adverse effects; Vaccines, Attenuated - genetics; Vaccines, Attenuated - immunology; Vaccines, Synthetic - administration & dosage; Vaccines, Synthetic - adverse effects; Vaccines, Synthetic - genetics; Vaccines, Synthetic - immunology; viral load; viral shedding; Virology; viruses; Live-attenuated vaccine; Recombinant virus vaccine; Pediatric vaccine; Parainfluenza; Human; Recombinant virus; Vaccine; Paramyxoviridae; Virus; Paramyxovirinae; Mononegavirales; Human parainfluenza virus 3; Infectivity; Attenuated strain; Child; Paramyxovirus
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2013.09.046

Highlights • rHPIV3cp45 vaccine was immunogenic and well-tolerated in seronegative young children. • A second dose of rHPIV3cp45 given 6 months later was restricted in those previously infected. • Antibody responses were boosted after a second dose of rHPIV3cp45. • A second dose of rHPIV3cp45 induced antibody responses in two previously uninfected children.